SARS-CoV-2 Pneumonia
8
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Macrophage Regulation of Ozone-Induced Lung Inflammation
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
Predictors of Respiratory Failure in SARS-Cov-2 Infection